Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2018 | ctDNA measurement via liquid biopsies in cancer of unknown primary

Kai-Keen Shiu • 9 Nov 2018
ESMO 2018
General

Kai-Keen Shiu, MRCP, PhD, of the University College London Hospitals NHS Foundation Trust, London, UK, discusses the methods and potential applications of circulating tumor (ct)DNA measurements obtained from liquid biopsies in cancer of unknown primary. Speaking from the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany, Dr Shiu provides an overview of the results obtained from his ctDNA study, where numerous deletions, amplifications and fusions in approximately 70 cancer genes were examined, higlighting the potential uses of ctDNA measurement in cancer diagnosis and management.

More from Kai-Keen Shiu

KEYNOTE-177: translating results for patients and clinicians
3:36
KEYNOTE-177: translating results for patients and clinicians
Kai-Keen Shiu • 17 Jan 2021
KEYNOTE-177 discussion: chemo-immunotherapy, pseudoprogression & biomarkers
6:57
KEYNOTE-177 discussion: chemo-immunotherapy, pseudoprogression & biomarkers
Kai-Keen Shiu • 17 Jan 2021
KEYNOTE-177: final PFS analysis of pembrolizumab in patients with MSI-H/dMMR mCRC
2:56
KEYNOTE-177: final PFS analysis of pembrolizumab in patients with MSI-H/dMMR mCRC
Kai-Keen Shiu • 17 Jan 2021
Current challenges and key developments in CRC
4:00
Current challenges and key developments in CRC
Kai-Keen Shiu • 27 Sep 2019

Related Videos

AI governance and validation in robotic cancer surgery
1:12
AI governance and validation in robotic cancer surgery
Marie Hanaoka • 1 Jul 2026
Does toxicity differ between patients treated with SABR for one versus five lesions?
0:39
Does toxicity differ between patients treated with SABR for one versus five lesions?
Robert Olson • 16 May 2026
5-year toxicity following SABR: insights from the SABR-5 trial
0:42
5-year toxicity following SABR: insights from the SABR-5 trial
Robert Olson • 16 May 2026
How should results from the SABR-5 trial guide future SABR studies?
1:05
How should results from the SABR-5 trial guide future SABR studies?
Robert Olson • 16 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals